Home
Storia in 2 fonti
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit designs.
- ·
usatoday.com
Novo to cut Ozempic and Wegovy prices amid intense competition
Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.
- ·
cnbc.com
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit designs.